Arena Pharmaceuticals, Inc. to Present at Two Upcoming Investor Conferences

SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announcedtoday that Jack Lief, Arena’s President and Chief Executive Officer, and Dominic P. Behan, Ph.D., Arena’s Senior Vice President and Chief Scientific Officer, are scheduled to present a corporate overview and update at two upcoming investor conferences at the Waldorf=Astoria in New York City.

• 14th Annual BIO CEO & Investor Conference
  Presentation: Tuesday, February 14, 2012, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time)
• Leerink Swann 2012 Global Healthcare Conference
  Presentation: Wednesday, February 15, 2012, at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time)

A live audio webcast of each presentation will be available under the investor relations section of Arena’s website at www.arenapharm.com. A replay of each presentation will be available for 30 days following the event. Please connect to Arena’s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors, an important class of validated drug targets, in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena is seeking marketing approval of its most advanced drug candidate, which is intended for weight management and has been assigned by the US Food and Drug Administration (FDA) a new Prescription Drug User Fee Act (PDUFA) target date of June 27, 2012.

Arena Pharmaceuticals® and Arena® are registered service marks of the company.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the therapeutic indication of Arena’s most advanced drug candidate, lorcaserin; seeking marketing approval of lorcaserin; the FDA’s review of the resubmitted lorcaserin NDA and the potential timing for the FDA to complete such review; and Arena’s focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain, and the FDA may not complete its review of the resubmitted lorcaserin NDA by the PDUFA date; the FDA advisory committee meeting for lorcaserin may not be held as expected; nonclinical and clinical data is voluminous and detailed, and regulatory agencies may interpret or weigh the importance of data differently and reach different conclusions than Arena or others, request additional information, have additional recommendations or change their guidance or requirements before or after approval; data and other information related to lorcaserin and Arena’s other research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory review or approval; Arena’s submission of a marketing authorization application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; unexpected or unfavorable new data; risks related to commercializing new products; Arena’s ability to obtain and defend its patents; the timing, success and cost of Arena’s research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; having adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena’s forward-looking statements are disclosed in Arena’s filings with the Securities and Exchange Commission. These forward-looking statements represent Arena’s judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

SOURCE Arena Pharmaceuticals, Inc.